EXLS · 10-Q · 2026Q1 · Full report

Healthcare and Life Sciences Growth

ExlService Holdings, Inc. · 2026-04-28 · Importance 73 · Surprise 66

Healthcare and Life Sciences revenue increased 21.0% year-over-year to $151.9 million in Q1 2026, driven largely by expansion within existing healthcare payer/provider and life sciences clients (20.5%). Gross margin in the segment rose 140 basis points to 45.3%, reflecting higher volumes in certain existing clients and operational leverage. EXL highlights payment integrity, revenue cycle, care management and life-sciences commercial/clinical offerings as drivers of demand, and the segment benefits from platform and analytics-led work. This represents one of the company’s strongest segment-level growth rates in the quarter.